Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW)

Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence

Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab

Supplemental Table 1. Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW).

Supplemental Table 2. Baseline Characteristics of Patients With Advanced BRAF-Mt Melanoma by 1L Treatment